Association of Age With Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
09 2021
Historique:
received: 02 02 2021
revised: 24 04 2021
accepted: 26 05 2021
pubmed: 13 6 2021
medline: 2 2 2022
entrez: 12 6 2021
Statut: ppublish

Résumé

To determine if older men with Gleason grade group (GG) 1 prostate cancer have a higher risk of having adverse pathology at radical prostatectomy after initially being managed with active surveillance (AS). A total of 365 patients with GG1 prostate cancer initially managed with AS followed by delayed radical prostatectomy were identified. The primary outcome was adverse pathology after delayed radical prostatectomy in the men that were <65 years vs. men ≥65 years at the initiation of AS. Adverse pathology was defined as GG ≥3 or pT3 or pN1. Multivariable Cox proportional hazards regression models were used to calculate risk of adverse pathological findings at radical prostatectomy by age group. At diagnosis, there were no significant differences in median prostate specific antigen density, percent positive biopsy cores, multiparametric magnetic resonance imaging (mpMRI) results or composite genomic classifier scores (derived from three commercially available genomic tests) between the two age groups. Men ≥65 years had more adverse pathology at radical prostatectomy (59.2% vs. 44.1%, P <0.01) and lower rates of biopsy upgrade-free survival and adverse pathology-free survival (log-rank P <0.01). On multivariable analysis age ≥65 years (Hazard Ratio (HR) 2.21, 95% Confidence Interval (CI) 1.57, 3.12) was associated with adverse pathology at radical prostatectomy. In separate multivariable analyses done for each age group, mpMRI (HR 3.33, 95% CI 1.01, 10.95) was predictor of adverse pathology in the group ≥65 years. Older patients might require closer monitoring on AS and additional testing such as mpMRI might improve their risk stratification.

Identifiants

pubmed: 34118228
pii: S0090-4295(21)00470-2
doi: 10.1016/j.urology.2021.05.044
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-95

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Claire M de la Calle (CM)

Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California. Electronic address: claire.delacalle@ucsf.edu.

Kevin Shee (K)

Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California.

Carissa E Chu (CE)

Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California.

Janet E Cowan (JE)

Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California.

Hao G Nguyen (HG)

Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California.

Peter R Carroll (PR)

Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH